Cargando…

Negative effect of the second dose of the BNT162b2 vaccine in a significant percentage of individuals with previous COVID infection

Detalles Bibliográficos
Autores principales:	Baos, Elvira, Delgado-Iribarren, Alberto, O´Connor, Silvia, Bardón, Ignacio, Alvaréz, Mar, Rodríguez-Avial, Iciar, Culebras, Esther
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570440/ https://www.ncbi.nlm.nih.gov/pubmed/34749010 http://dx.doi.org/10.1016/j.ijid.2021.11.002

Ejemplares similares

Synergy of Linezolid with Several Antimicrobial Agents against Linezolid-Methicillin-Resistant Staphylococcal Strains
por: Valderrama, María-José, et al.
Publicado: (2020)

Utilidad de MALDI-TOF y REP-PCR frente a PFGE para el estudio epidemiológico de Acinetobacter baumannii
por: García-Salguero, Cristina, et al.
Publicado: (2021)

Resistance to fosfomycin is increasing and is significantly associated with extended-spectrum β-lactamase-production in urinary isolates of Escherichia coli
por: Ríos, Esther, et al.
Publicado: (2022)

Evolution of antibody titers after two doses of mRNA Pfizer-BioNTech vaccine and effect of the third dose in nursing home residents
por: Rodríguez-Avial, Iciar, et al.
Publicado: (2023)

High performance of the automated ADVIA Centaur Systems SARS-CoV-2 Antigen Assay in nasopharyngeal samples with high viral load
por: Ríos, Esther, et al.
Publicado: (2022)

Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?
por: Robertson, John F R, et al.
Publicado: (2021)

The clinical course of patients with previous acute and recurrent pericarditis receiving the BNT162b2 vaccine
por: Wasserstrum, Yishay, et al.
Publicado: (2022)

Antibody response after second BNT162b2 dose in allogeneic HSCT recipients
por: Redjoul, Rabah, et al.
Publicado: (2021)

The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects
por: Vicenti, Ilaria, et al.
Publicado: (2021)

Acute Myocarditis Following the Administration of the Second BNT162b2 COVID-19 Vaccine Dose
por: Miqdad, Mohammed A, et al.
Publicado: (2021)

DIAPHRAGMATIC PARALYSIS FOLLOWING SECOND DOSE OF THE BNT162B2 MRNA COVID-19 VACCINE
por: PRUDENTI, JOHN A, et al.
Publicado: (2022)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
por: Manisty, Charlotte, et al.
Publicado: (2021)

Antibody response to first and second dose of BNT162b2 in a cohort of characterized healthcare workers
por: Padoan, Andrea, et al.
Publicado: (2021)

A case of reactivation of varicella–zoster virus after BNT162b2 vaccine second dose?
por: Santovito, Luca Spiro, et al.
Publicado: (2021)

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1
por: Shrotri, Madhumita, et al.
Publicado: (2021)

Temporal relation between second dose BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection
por: Ammirati, Enrico, et al.
Publicado: (2021)

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2
por: Ebinger, Joseph E., et al.
Publicado: (2021)

WITHDRAWN: Temporal relation between second dose BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection
por: Ammirati, Enrico, et al.
Publicado: (2021)

Immunogenicity of a BNT162b2 vaccine booster in health-care workers
por: Saiag, Esther, et al.
Publicado: (2021)

Effusive–constrictive pericarditis after the second dose of BNT162b2 vaccine (Comirnaty): a case report
por: Viani, Giacomo Maria, et al.
Publicado: (2022)

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine
por: Prendecki, Maria, et al.
Publicado: (2021)

Evaluation of the immune response to COVID-19 vaccine mRNA BNT162b2 and correlation with previous COVID-19 infection
por: Bongiovanni, Marco, et al.
Publicado: (2021)

Antibody Response after BNT162b2 Vaccination in Healthcare Workers Previously Exposed and Not Exposed to SARS-CoV-2
por: Salvaggio, Marcello, et al.
Publicado: (2021)

Previous COVID-19 infection, but not Long-COVID, is associated with increased adverse events following BNT162b2/Pfizer vaccination
por: Raw, Rachael Kathleen, et al.
Publicado: (2021)

Breakthrough infections with SARS-CoV-2 omicron efficiently boost antibodies from previous BNT162b2 vaccinations
por: Perkmann, Thomas, et al.
Publicado: (2023)

Humoral and Cellular Immunity Are Significantly Affected in Renal Transplant Recipients, following Vaccination with BNT162b2
por: Fylaktou, Asimina, et al.
Publicado: (2023)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

Erythema Multiforme after BNT162b2 Vaccination
por: Katayama, Sho, et al.
Publicado: (2022)

Robust Antibody Responses to the BNT162b2 mRNA Vaccine Occur Within a Week After the First Dose in Previously Infected Individuals and After the Second Dose in Uninfected Individuals
por: Hirotsu, Yosuke, et al.
Publicado: (2021)

Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose
por: Vicenti, Ilaria, et al.
Publicado: (2021)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations
por: Efrati, Shai, et al.
Publicado: (2021)

Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals
por: Muena, Nicolás A., et al.
Publicado: (2022)

Different decay of antibody response and VOC sensitivity in naïve and previously infected subjects at 15 weeks following vaccination with BNT162b2
por: Siracusano, Gabriel, et al.
Publicado: (2022)

SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals
por: Lombardi, Andrea, et al.
Publicado: (2021)

Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive
por: Kontopoulou, Konstantina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uodvp7nkip6felvp1ouferoj65